|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-2-23
|
|
pubmed:abstractText |
For decades, hundreds of different human tumor type-specific cell lines have been used in experimental cancer research as models for their respective tumors. The veracity of experimental results for a specific tumor type relies on the correct derivation of the cell line. In a worldwide effort, we verified the authenticity of all available esophageal adenocarcinoma (EAC) cell lines. We proved that the frequently used cell lines SEG-1 and BIC-1 and the SK-GT-5 cell line are in fact cell lines from other tumor types. Experimental results based on these contaminated cell lines have led to ongoing clinical trials recruiting EAC patients, to more than 100 scientific publications, and to at least three National Institutes of Health cancer research grants and 11 US patents, which emphasizes the importance of our findings. Widespread use of contaminated cell lines threatens the development of treatment strategies for EAC.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-11252900,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-11407472,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-11416159,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-11520067,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-11832445,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-15046208,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-15131795,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-15231484,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-15261138,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-15300175,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-15964304,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-17804709,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-18287387,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-18512153,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-18676772,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-18787394,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-18840136,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-20075369,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-2787530,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-6451928,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-7394535,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-8334620,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20075370-9010035
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
pubmed-author:AltorkiNasser KNK,
pubmed-author:AlvarezHectorH,
pubmed-author:BeerDavid GDG,
pubmed-author:BoonstraJurjen JJJ,
pubmed-author:ChavesPaulaP,
pubmed-author:DarntonS JaneSJ,
pubmed-author:DinjensWinand N MWN,
pubmed-author:EshlemanJames RJR,
pubmed-author:KlimstraDavid SDS,
pubmed-author:PereiraA DiasAD,
pubmed-author:RibeiroCatarinaC,
pubmed-author:RoqueLúciaL,
pubmed-author:SchrumpDavid SDS,
pubmed-author:ShimadaYutakaY,
pubmed-author:TangLaura HLH,
pubmed-author:TilanusHugo WHW,
pubmed-author:XXX,
pubmed-author:van DekkenHermanH,
pubmed-author:van MarionRonaldR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
24
|
|
pubmed:volume |
102
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
271-4
|
|
pubmed:dateRevised |
2011-9-26
|
|
pubmed:meshHeading |
pubmed-meshheading:20075370-Adenocarcinoma,
pubmed-meshheading:20075370-Antineoplastic Agents,
pubmed-meshheading:20075370-Benzenesulfonates,
pubmed-meshheading:20075370-Biomedical Research,
pubmed-meshheading:20075370-Carcinoma,
pubmed-meshheading:20075370-Carcinoma, Large Cell,
pubmed-meshheading:20075370-Cell Line, Tumor,
pubmed-meshheading:20075370-Clinical Trials as Topic,
pubmed-meshheading:20075370-Colorectal Neoplasms,
pubmed-meshheading:20075370-DNA Fingerprinting,
pubmed-meshheading:20075370-Esophageal Neoplasms,
pubmed-meshheading:20075370-Humans,
pubmed-meshheading:20075370-Lung Neoplasms,
pubmed-meshheading:20075370-National Institutes of Health (U.S.),
pubmed-meshheading:20075370-Oligonucleotides,
pubmed-meshheading:20075370-Oligopeptides,
pubmed-meshheading:20075370-Protein Kinase Inhibitors,
pubmed-meshheading:20075370-Pyridines,
pubmed-meshheading:20075370-Stomach Neoplasms,
pubmed-meshheading:20075370-Tandem Repeat Sequences,
pubmed-meshheading:20075370-Telomerase,
pubmed-meshheading:20075370-United States
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
|
|
pubmed:affiliation |
Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
|
|
pubmed:publicationType |
Journal Article
|
